According to Trevena's latest financial reports the company has a price-to-book ratio of 2.02.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2023-12-31 | 3.09 | 384.62% |
2022-12-31 | 0.6370 | -57.04% |
2021-12-31 | 1.48 | -54.93% |
2020-12-31 | 3.29 | 24.91% |
2019-12-31 | 2.63 | 208.99% |
2018-12-31 | 0.8525 | -70.38% |
2017-12-31 | 2.88 | -26.5% |
2016-12-31 | 3.92 | 5.08% |
2015-12-31 | 3.73 | 57.55% |
2014-12-31 | 2.37 | |
2013-12-31 | N/A | |
2012-12-31 | N/A |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Amgen AMGN | 23.2 | 1,051.21% | ๐บ๐ธ USA |
Merck MRK | 8.83 | 337.48% | ๐บ๐ธ USA |
Cytokinetics
CYTK | -17.7 | -976.28% | ๐บ๐ธ USA |
AcelRx Pharmaceuticals
ACRX | 1.03 | -48.79% | ๐บ๐ธ USA |
Cara Therapeutics
CARA | 0.6553 | -67.53% | ๐บ๐ธ USA |